Project
Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.
Ongoing - recruitment active · 2024 until 2028
Fischer Stefanie, Dei Cas Alissa
Type
Clinical Studies
Range
Multicentric, KSSG as main centre
Units
Status
Ongoing - recruitment active
Start Date
2024
End Date
2028
Financing
Industry
Labels
prostate cancer